http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MD-4786-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9ca0632596f3342a71f604d9152b9e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00a421ab71bd49a451d0a49d23a082c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3013792496d29152b189f60720f2fe0
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C61-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-96
filingDate 2020-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec913894cb0298b9b93888525907563c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21e0130227904c1a9f0a0b5dda9531b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a552e8e017351893cccc9501327e43d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96a1dd267600ef0310216b156d3c50e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_457a4098cd7b7d70e3a5e78d8ffe1822
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aac7a046d9cf7e09fcde7af78fa66b3
publicationDate 2022-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MD-4786-C1
titleOfInvention New spiro-γ-lactams, derivatives of ent-kaurenoic acid, with selective cytotoxic activity
abstract The invention relates to the chemistry of natural compounds and medicinal chemistry, in particular to ent-kaurenoic acid derivatives containing a spiro-γ-lactam functional group, which have selective cytotoxic properties against human cancer cells and can be used as chemotherapeutic agents for the treatment oncological diseases. According to the invention, two derivatives of ent-kaurenoic acid with the following structural formulas are claimed: The claimed compounds possess selective cytotoxic activity against tumor cell lines Capan-1 (pancreatic adenocarcinoma), Hap-1 (chronic myeloid leukemia), HCT-116 (colorectal carcinoma) and NCI-H460 (lung carcinoma).
priorityDate 2020-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3034087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554089

Total number of triples: 23.